Literature DB >> 25981401

Effects of phosphodiesterase-5 inhibitor on ischemic kidney injury during nephron sparing surgery: quantitative assessment by NGAL and KIM-1.

Yousef Lahoud1, Osamah Hussein1, Amjad Shalabi2, Omri Nativ3, Hoda Awad3, Mogher Khamaisi4, Ibrahim Matar5, Ofer Nativ6, Zaid Abassi7,8.   

Abstract

PURPOSE: Interruption of renal blood flow is often necessary during nephron sparing surgery (NSS) and can induce renal injury. This study examines whether tadalafil, a phosphodiesterase-5 (PDE-5) inhibitor and well-known vasodilator, exerts nephroprotective effects in patients undergoing NSS.
METHODS: This non-randomized study included 49 patients with enhancing solid renal mass. All patients were subjected to open NSS during which clamping the renal artery was performed. Twenty-two patients were pretreated with tadalafil 1 day prior NSS and 2 days following surgery. The other 27 patients underwent the same surgical procedure but did not receive tadalafil (controls). Urine samples were collected before surgery and following renal pedicle clamp removal. Urine levels of NGAL and KIM-1, two novel biomarkers for acute kidney injury (AKI), were determined.
RESULTS: Clamping the renal artery induced kidney dysfunction as reflected by increases in urinary NGAL and KIM-1 in all participants. These increases in urinary NGAL and KIM-1 excretion were evident 1 h after renal ischemia and lasted for 72 and 24 h, respectively. Pretreatment with tadalafil reduced the absolute urinary excretion of KIM-1, but not of NGAL. Although the incidence of AKI was comparable between tadalafil-treated and untreated NSS subjects, the elevation in serum creatinine (SCr) was significantly attenuated in tadalafil-treated group as compared with NSS controls.
CONCLUSIONS: Tadalafil exerts nephroprotective effects in AKI following NSS, as was evident by reduced urinary excretion of KIM-1 and attenuation of SCr elevation. Carefully controlled large clinical studies are needed before defining the role of PDE-5 inhibition therapy in these patients.

Entities:  

Keywords:  Acute kidney injury; KIM-1; NGAL; Nephron sparing surgery; Tadalafil

Mesh:

Substances:

Year:  2015        PMID: 25981401     DOI: 10.1007/s00345-015-1579-3

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  34 in total

1.  Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery.

Authors:  Jaya Mishra; Catherine Dent; Ridwan Tarabishi; Mark M Mitsnefes; Qing Ma; Caitlin Kelly; Stacey M Ruff; Kamyar Zahedi; Mingyuan Shao; Judy Bean; Kiyoshi Mori; Jonathan Barasch; Prasad Devarajan
Journal:  Lancet       Date:  2005 Apr 2-8       Impact factor: 79.321

Review 2.  Challenges and advances in the treatment of AKI.

Authors:  Gur P Kaushal; Sudhir V Shah
Journal:  J Am Soc Nephrol       Date:  2014-01-30       Impact factor: 10.121

3.  Sutureless nephron-sparing surgery: use of albumin glutaraldehyde tissue adhesive (BioGlue).

Authors:  G Hidas; A Kastin; M Mullerad; J Shental; B Moskovitz; O Nativ
Journal:  Urology       Date:  2006-03-29       Impact factor: 2.649

4.  Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling.

Authors:  Anindita Das; Lei Xi; Rakesh C Kukreja
Journal:  J Biol Chem       Date:  2005-01-24       Impact factor: 5.157

5.  The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size.

Authors:  C Sesti; V Florio; E G Johnson; R A Kloner
Journal:  Int J Impot Res       Date:  2006-07-20       Impact factor: 2.896

6.  Elective nephron sparing surgery should become standard treatment for small unilateral renal cell carcinoma: Long-term survival data of 216 patients.

Authors:  F Becker; S Siemer; U Humke; M Hack; M Ziegler; M Stöckle
Journal:  Eur Urol       Date:  2005-12-09       Impact factor: 20.096

7.  cGMP-selective phosphodiesterase inhibitors stimulate mitochondrial biogenesis and promote recovery from acute kidney injury.

Authors:  Ryan M Whitaker; Lauren P Wills; L Jay Stallons; Rick G Schnellmann
Journal:  J Pharmacol Exp Ther       Date:  2013-09-16       Impact factor: 4.030

Review 8.  Acute renal failure: definitions, diagnosis, pathogenesis, and therapy.

Authors:  Robert W Schrier; Wei Wang; Brian Poole; Amit Mitra
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

9.  Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats.

Authors:  Dae Eun Choi; Jin Young Jeong; Beom Jin Lim; Sarah Chung; Yoon Kyung Chang; Sang Ju Lee; Ki Ryang Na; Seok Young Kim; Young Tai Shin; Kang Wook Lee
Journal:  Am J Physiol Renal Physiol       Date:  2009-05-27

10.  Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes.

Authors:  Venkata S Sabbisetti; Sushrut S Waikar; Daniel J Antoine; Adam Smiles; Chang Wang; Abinaya Ravisankar; Kazumi Ito; Sahil Sharma; Swetha Ramadesikan; Michelle Lee; Rebeccah Briskin; Philip L De Jager; Thanh Thu Ngo; Mark Radlinski; James W Dear; Kevin B Park; Rebecca Betensky; Andrzej S Krolewski; Joseph V Bonventre
Journal:  J Am Soc Nephrol       Date:  2014-06-05       Impact factor: 10.121

View more
  3 in total

1.  The evaluation of acute kidney injury due to ischemia by urinary neutrophil gelatinase-induced lipocalin (uNGAL) measurement in patients who underwent partial nephrectomy.

Authors:  Cagri Akpinar; Ozlem Dogan; Eralp Kubilay; Mehmet Ilker Gokce; Evren Suer; Omer Gulpinar; Sumer Baltaci
Journal:  Int Urol Nephrol       Date:  2020-09-26       Impact factor: 2.370

2.  Acute Renal Failure Following Near-Drowning.

Authors:  Yuri Gorelik; Said Darawshi; Hiba Yaseen; Zaid Abassi; Samuel N Heyman; Mogher Khamaisi
Journal:  Kidney Int Rep       Date:  2018-03-01

Review 3.  Current Concepts on the Reno-Protective Effects of Phosphodiesterase 5 Inhibitors in Acute Kidney Injury: Systematic Search and Review.

Authors:  Georgios Georgiadis; Ioannis-Erineos Zisis; Anca Oana Docea; Konstantinos Tsarouhas; Irene Fragkiadoulaki; Charalampos Mavridis; Markos Karavitakis; Stavros Stratakis; Kostas Stylianou; Christina Tsitsimpikou; Daniela Calina; Nikolaos Sofikitis; Aristidis Tsatsakis; Charalampos Mamoulakis
Journal:  J Clin Med       Date:  2020-04-29       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.